Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cogent Biosciences, Inc. COGT
$11.50
+$0.12 (1.05%)
На 18:00, 12 мая 2023
+76.78%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
796023096.00000000
-
week52high
18.07
-
week52low
3.79
-
Revenue
0
-
P/E TTM
-6
-
Beta
-0.39606700
-
EPS
-2.29000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 11:00
Описание компании
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Guggenheim | Buy | 28 июн 2022 г. | |
| SVB Leerink | Outperform | Outperform | 13 июн 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 05 ноя 2021 г. |
| HC Wainwright & Co. | Buy | 11 окт 2021 г. | |
| Piper Sandler | Overweight | 23 дек 2020 г. | |
| SVB Leerink | Outperform | Outperform | 17 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 05 янв 2023 г. |
| Needham | Buy | 14 дек 2022 г. | |
| Guggenheim | Buy | Buy | 13 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Ferrante Karen Jean | A | 1862 | 1862 | 03 янв 2023 г. |
| Ros Matthew | A | 1792 | 1792 | 03 янв 2023 г. |
| Ros Matthew | A | 1419 | 1419 | 03 окт 2022 г. |
| Ferrante Karen Jean | A | 1474 | 1474 | 03 окт 2022 г. |
| Ros Matthew | A | 2194 | 2194 | 01 июл 2022 г. |
| Ferrante Karen Jean | A | 2279 | 2279 | 01 июл 2022 г. |
| Sachs Jessica | A | 622 | 622 | 30 июн 2022 г. |
| Fairmount Funds Management LLC | A | 2472124 | 1200000 | 16 июн 2022 г. |
| Ferrante Karen Jean | A | 30700 | 30700 | 07 июн 2022 г. |
| Morris Arlene | A | 30700 | 30700 | 07 июн 2022 г. |
Новостная лента
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
GlobeNewsWire
12 апр 2023 г. в 08:00
WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the following upcoming virtual investor conferences:
These Are the Top 10 Holdings of David Kim
24/7 Wall Street
06 мар 2023 г. в 22:55
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 2012).
Cogent Biosciences: Bezuclastinib's Potential In Treating Gastrointestinal Stromal Tumors
Seeking Alpha
28 февр 2023 г. в 02:17
Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointestinal Stromal Tumors. Bezuclastinib is a promising tyrosine kinase inhibitor that targets KIT exon 17/18 mutations, commonly found in patients with advanced and/or treatment-resistant GIST.
Cogent Biosciences: Multiple Inflection Points For FY23, Hold For Now
Seeking Alpha
27 дек 2022 г. в 19:02
Cogent Biosciences, Inc. is building momentum around its bezuclastinib compound. FY22 saw a number of positive advancements of the company's pipeline.
Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
GlobeNewsWire
05 дек 2022 г. в 08:00
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Monday, December 12, 2022 at 8:00 a.m. ET (7:00 a.m. CT) to discuss updated clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the 64th American Society of Hematology (ASH) Annual Meeting.